Can Long-Acting injections stop stimulant psychosis from worsening?

NCT ID NCT03485417

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two long-acting injectable medications, aripiprazole and paliperidone, in 165 people who use stimulants and have psychosis. The goal was to see if these drugs could better manage psychosis and prevent progression to chronic schizophrenia compared to standard treatment. Participants were randomly assigned to one of the two medications or to usual care, and their symptoms were tracked over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aripiprazole and paliperidone (long-acting injectable forms)
What this could lead to
If successful, this could provide an evidence-based treatment strategy to better manage psychosis in people who use stimulants and reduce the risk of long-term dependence.
What could go wrong
This is a completed Phase 2/3 trial with 165 participants in Hong Kong, so results may not apply to other populations. The medications have side effects, and the study compares them to usual care, which may limit how broadly the findings can be used.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PHARMACOTHERAPY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Queen Mary Hospital

    Hong Kong, 000000, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.